InsidersTradesSigma
MiNK Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the MiNK Therapeutics, Inc. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, MiNK Therapeutics, Inc. has logged 77 public disclosures. Market capitalisation: €58.1m. The latest transaction was disclosed on 2 June 2026 (Attribution). Among the most active insiders: Corvese Brian. The full history is openly available.
77
Insider Decl.
0
Thresholds
€29m
10 ops.
Buy Volume
€86,048
1 ops.
Sell Volume
36Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 2 June 2026
Declarations77 total
1,640 shares@ US$10.906.5% of flowCommon StockSEC:0001193125-26-253468:0
1,444 shares@ US$12.380.029% mcap6.6% of flowCommon StockSEC:0001193125-26-253468:1
1,491 shares@ US$10.906.8% of flowCommon StockSEC:0001193125-26-253466:0
1,313 shares@ US$12.380.026% mcap6.9% of flowCommon StockSEC:0001193125-26-253466:1
10,024 shares@ US$11.120.18% mcap28.7% of flowCommon StockSEC:0001193125-26-012914:0
10,024 shares@ US$11.1228.7% of flowCommon StockSEC:0001193125-26-012914
5,351 shares@ US$15.3621.3% of flowCommon StockSEC:0001193125-25-230098
5,351 shares@ US$15.360.13% mcap21.3% of flowCommon StockSEC:0001193125-25-230098:0
2,033 shares@ US$8.797.4% of flowCommon StockSEC:0000950170-25-033522:0
1,593 shares@ US$8.798.0% of flowCommon StockSEC:0000950170-25-033525:0
1,536 shares@ US$8.7960.4% of flowCommon StockSEC:0000950170-25-033540:0
2,019 shares@ US$8.798.5% of flowCommon StockSEC:0000950170-25-033523:0
1,849 shares@ US$8.797.7% of flowCommon StockSEC:0000950170-25-033528:0
12,286 shares@ US$0.7339.6% of flowCommon StockSEC:0000950170-24-134524:0
24,400 shares@ US$0.737.2% of flowCommon StockSEC:0000950170-24-132524:0
20,987 shares@ US$0.737.2% of flowCommon StockSEC:0000950170-24-132520:0
20,476 shares@ US$0.738.4% of flowCommon StockSEC:0000950170-24-132518:0
24,229 shares@ US$0.738.3% of flowCommon StockSEC:0000950170-24-132525:0
21,802 shares@ US$0.826.9% of flowCommon StockSEC:0000950170-24-103740:0
21,649 shares@ US$0.828.0% of flowCommon StockSEC:0000950170-24-103750:0
18,295 shares@ US$0.828.1% of flowCommon StockSEC:0000950170-24-103745:0
18,753 shares@ US$0.826.9% of flowCommon StockSEC:0000950170-24-103749:0
17,967 shares@ US$0.997.0% of flowCommon StockSEC:0000950170-24-069211:0
15,077 shares@ US$0.998.2% of flowCommon StockSEC:0000950170-24-069212:0
15,454 shares@ US$0.996.9% of flowCommon StockSEC:0000950170-24-069216:0
25 of 77 declarations
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. (ticker INKT) is a U.S.-listed biotechnology company trading on the NASDAQ market in the United States, with principal executive offices in New York City. For investors, MiNK is a clinical-stage biotech focused on next-generation cell therapy, offering a high-risk, high-upside profile typical of early pipeline companies. The company was originally incorporated in 2017 as AgenTus Biosciences and later changed its name to MiNK Therapeutics in June 2021. It has strong historical ties to Agenus and has built its strategy around a proprietary allogeneic invariant natural killer T-cell (iNKT) platform designed for off-the-shelf use, avoiding the patient-specific manufacturing burden associated with many autologous cell therapies. MiNK’s core business is the discovery, development, manufacturing, and potential commercialization of iNKT-based therapies aimed at modulating immune function in oncology and immune-mediated diseases. Its lead asset, agenT-797, is a cryopreserved allogeneic iNKT cell therapy being studied across multiple settings, including solid tumors, graft-versus-host disease (GvHD), and severe inflammatory lung disease such as acute respiratory distress syndrome (ARDS). The company has also described a pipeline of next-generation engineered iNKT programs, including CAR-iNKT approaches and antigen-targeted constructs, alongside external collaborations intended to broaden the platform into pediatric cancers and additional unmet-need indications. From a competitive standpoint, MiNK seeks differentiation through three main attributes: an allogeneic, scalable platform; a broader immune-restoration thesis beyond oncology alone; and in-house manufacturing capabilities intended to improve reproducibility and support clinical execution. This positions the company differently from more conventional CAR-T developers, which often rely on individualized workflows that can be more complex and expensive. However, MiNK remains early-stage, meaning its investment case depends heavily on clinical validation, partner funding, and careful capital allocation. During 2025 and into 2026, MiNK reported a steady flow of clinical and strategic updates, including Phase 2 progress for agenT-797 in checkpoint-refractory gastroesophageal cancer, publications and conference presentations in ARDS, expansion work in idiopathic pulmonary fibrosis (IPF), and a collaboration with C-Further to advance a PRAME-targeted iNKT program in pediatric oncology. These developments reinforce the company’s catalyst-driven profile, but also underscore that it remains a speculative NASDAQ biotech whose valuation will be shaped primarily by clinical readouts and execution rather than near-term commercial revenue.
